TORONTO, ONTARIO--(Marketwired - May 9, 2013) - Biologix Hair Inc. (OTCBB:BLGX)(OTCQB:BLGX) has appointed David Perez-Meza, MD to the Company's Medical Advisory Board, where he will serve with Dr. Alan J. Bauman, Dr. Edward A.M. Ball, Dr. Arthur G. Handal and Dr. Craig Ziering, Medical Advisory Board Chairman.
David Perez-Meza, MD, is clinical director of Ziering Medical Spain and associate director of clinical research for Ziering Worldwide, a private practice dedicated exclusively to the specialty of hair restoration and creating positive change for patients. In addition, Dr. Perez-Meza is president of Permanent Hair Solutions in Mexico City, clinical consultant to Ameriderm Research in Maitland, Florida, on the Board of Governors of the International Society of Hair Restoration Surgery (ABHRS) and a member of the Scientific Advisory Council of the Hair Foundation.
Dr. Perez-Meza was born in Mexico and graduated from the Military Medical School in Mexico City after he specialized in plastic, aesthetic and reconstructive surgery for three years. He was an active member of the Presidential Medical Corps and in that capacity served as the personal physician to the former Mexican presidents. Dr. Perez-Meza retired with a Lt. Colonel status in 1996, after serving in the Mexican Army for 26 years. He received advanced training in hair restoration surgery in the United States thereafter.
From 1999 to 2007, Dr. Perez-Meza was fellowship instructor, research director and director of Latin America for Medical Hair Restoration. In 2001 he became the first Hispanic diplomat of the American Board of Hair Restoration Surgery. He is a board director and member of the Oral and Written Examiners Committee of the American Board of Hair Restoration Surgery, chairman of the Pro Bono Program Committee of the International Society of Hair Restoration Surgeons (ISHRS) and past-member of the Live Surgery Workshop and Continual Medical Education Committees of the ISHRS. Dr. Perez-Meza is the co-chairman of the Orlando Live Surgery Workshop (2001 to date).
Dr. Perez-Meza has authored numerous publications and research studies. He has served as a consultant for many companies, as well as being a sought-after speaker. He has received ten ISHRS Research Grant Awards and in 1997 received the Platinum Follicle Award from the ISHRS.
Biologix CEO and Chairman Ron Holland stated, "We appreciate Dr. Perez-Meza's willingness to assist Biologix Hair Inc. through Board membership and look forward to his valuable contributions as we continue to grow forward."
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment - the Biologix Hair Therapy System™ - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive - the essence of the Biologix Hair Therapy System™ - were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.
Additionally, on May 11, 2012, Venable LLP, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 144 countries have as of now contracted, including Canada and the United States.
Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™, if and when FDA and other major market approvals are forthcoming.
As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.
Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy System™ is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.
To learn more about Clinician Licensing opportunities, please visit http://www.biologixhair.com/licensing/clinici...g-options/ or call toll free +1 855.737.0333 or +1 647.344.5900.
Disclaimer
This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities as well as the ability for Biologix to obtain adequate financing to meet its business objectives. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.
